FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2131966144> ?p ?o ?g. }

• W2131966144 endingPage "240" @default.
• W2131966144 startingPage "231" @default.
• W2131966144 abstract "Few trials of adjuvant breast radiotherapy have incorporated patient-reported breast symptoms and related areas of quality of life. We assessed these measures in a quality-of-life study that was part of the randomised START (Standardisation of Breast Radiotherapy) trials.In START trial A, 2236 patients were randomly assigned to receive either 39 Gy or 41.6 Gy delivered in 13 fractions over 5 weeks or a global standard of 50 Gy in 25 fractions. In START trial B, 2215 women were randomly assigned to receive either 40 Gy in 15 fractions over 3 weeks or the same control regimen (50 Gy in 25 fractions) as in trial A. 2739 patients were eligible for the quality-of-life study of whom 2208 (81%) were accrued (1129 patients from trial A and 1079 from trial B). Participants completed the EORTC QLQ-C30 and BR23 questionnaires and protocol-specific radiotherapy items up to 5 years after radiotherapy. We compared results across regimens with generalised estimating equations and survival analyses. The START trials are registered, ISRCTN59368779.At 5 years, up to 40% women reported moderate or marked changes to the breast after radiotherapy, and arm and shoulder pain affected up to a third of patients. Breast symptoms and body image concerns reduced over time. Rates of radiotherapy adverse effects were lower for the 39 Gy regimen in trial A and the 40 Gy regimen in trial B, compared with the 50 Gy control regimen; rates of radiotherapy adverse effects were similar between the 41.6 Gy and 50 Gy regimens in trial A. Adverse change in skin appearance was significantly lower for patients who received 39 Gy compared with those who received 50 Gy (HR 0.63, 95% CI 0.47-0.84) and for those who received 40 Gy compared with those who received 50 Gy (0.76, 0.60-0.97); no significant difference was observed between patients who received 41.6 Gy and those who received 50 Gy in trial A (0.83, 0.63-1.08). Patient self-ratings of breast symptoms discriminated a 10% difference in randomised dose intensity. Up to a third of women reported moderate or marked pain in the arm and shoulder over 5 years whilst more than 10% experienced moderate or marked arm and hand swelling, with no significant difference in arm/shoulder subscale scores between the regimens in trial A or trial B; many baseline arm and shoulder symptoms were associated with prior surgery.A substantial proportion of women report moderate or marked breast, arm, and shoulder symptoms over 5 years of follow-up after radiotherapy, but with no detriment to body image. Nonetheless, most patients stand to gain from hypofractionated radiotherapy regimens with a potential for fewer adverse effects; this strengthens the evidence from the START trials for hypofractionated regimens for women requiring radiotherapy for early breast cancer.Cancer Research UK, UK Medical Research Council, UK Department of Health." @default.
• W2131966144 created "2016-06-24" @default.
• W2131966144 creator A5006665510 @default.
• W2131966144 creator A5008555547 @default.
• W2131966144 creator A5025460339 @default.
• W2131966144 creator A5033149434 @default.
• W2131966144 creator A5036027629 @default.
• W2131966144 creator A5075653141 @default.
• W2131966144 date "2010-03-01" @default.
• W2131966144 modified "2023-10-10" @default.
• W2131966144 title "Comparison of patient-reported breast, arm, and shoulder symptoms and body image after radiotherapy for early breast cancer: 5-year follow-up in the randomised Standardisation of Breast Radiotherapy (START) trials" @default.
• W2131966144 cites W1830334259 @default.
• W2131966144 cites W1848007259 @default.
• W2131966144 cites W1917059214 @default.
• W2131966144 cites W1966642934 @default.
• W2131966144 cites W1972795025 @default.
• W2131966144 cites W1986977828 @default.
• W2131966144 cites W1993168640 @default.
• W2131966144 cites W1999465640 @default.
• W2131966144 cites W2014585297 @default.
• W2131966144 cites W2015529238 @default.
• W2131966144 cites W2023209653 @default.
• W2131966144 cites W2033625667 @default.
• W2131966144 cites W2040190693 @default.
• W2131966144 cites W2077823756 @default.
• W2131966144 cites W2082400061 @default.
• W2131966144 cites W2086296188 @default.
• W2131966144 cites W2091603538 @default.
• W2131966144 cites W2097823108 @default.
• W2131966144 cites W2098843846 @default.
• W2131966144 cites W2123481594 @default.
• W2131966144 cites W2137661780 @default.
• W2131966144 cites W2143899676 @default.
• W2131966144 cites W2145786239 @default.
• W2131966144 cites W2149860264 @default.
• W2131966144 cites W2149899773 @default.
• W2131966144 cites W2167571044 @default.
• W2131966144 cites W2169473093 @default.
• W2131966144 cites W2226378258 @default.
• W2131966144 cites W3021410191 @default.
• W2131966144 cites W4245885048 @default.
• W2131966144 doi "https://doi.org/10.1016/s1470-2045(09)70382-1" @default.
• W2131966144 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20138809" @default.
• W2131966144 hasPublicationYear "2010" @default.
• W2131966144 type Work @default.
• W2131966144 sameAs 2131966144 @default.
• W2131966144 citedByCount "194" @default.
• W2131966144 countsByYear W21319661442012 @default.
• W2131966144 countsByYear W21319661442013 @default.
• W2131966144 countsByYear W21319661442014 @default.
• W2131966144 countsByYear W21319661442015 @default.
• W2131966144 countsByYear W21319661442016 @default.
• W2131966144 countsByYear W21319661442017 @default.
• W2131966144 countsByYear W21319661442018 @default.
• W2131966144 countsByYear W21319661442019 @default.
• W2131966144 countsByYear W21319661442020 @default.
• W2131966144 countsByYear W21319661442021 @default.
• W2131966144 countsByYear W21319661442022 @default.
• W2131966144 countsByYear W21319661442023 @default.
• W2131966144 crossrefType "journal-article" @default.
• W2131966144 hasAuthorship W2131966144A5006665510 @default.
• W2131966144 hasAuthorship W2131966144A5008555547 @default.
• W2131966144 hasAuthorship W2131966144A5025460339 @default.
• W2131966144 hasAuthorship W2131966144A5033149434 @default.
• W2131966144 hasAuthorship W2131966144A5036027629 @default.
• W2131966144 hasAuthorship W2131966144A5075653141 @default.
• W2131966144 hasBestOaLocation W21319661441 @default.
• W2131966144 hasConcept C121608353 @default.
• W2131966144 hasConcept C126322002 @default.
• W2131966144 hasConcept C141071460 @default.
• W2131966144 hasConcept C159110408 @default.
• W2131966144 hasConcept C168563851 @default.
• W2131966144 hasConcept C1862650 @default.
• W2131966144 hasConcept C197934379 @default.
• W2131966144 hasConcept C2779951463 @default.
• W2131966144 hasConcept C2781413609 @default.
• W2131966144 hasConcept C509974204 @default.
• W2131966144 hasConcept C530470458 @default.
• W2131966144 hasConcept C535046627 @default.
• W2131966144 hasConcept C71924100 @default.
• W2131966144 hasConceptScore W2131966144C121608353 @default.
• W2131966144 hasConceptScore W2131966144C126322002 @default.
• W2131966144 hasConceptScore W2131966144C141071460 @default.
• W2131966144 hasConceptScore W2131966144C159110408 @default.
• W2131966144 hasConceptScore W2131966144C168563851 @default.
• W2131966144 hasConceptScore W2131966144C1862650 @default.
• W2131966144 hasConceptScore W2131966144C197934379 @default.
• W2131966144 hasConceptScore W2131966144C2779951463 @default.
• W2131966144 hasConceptScore W2131966144C2781413609 @default.
• W2131966144 hasConceptScore W2131966144C509974204 @default.
• W2131966144 hasConceptScore W2131966144C530470458 @default.
• W2131966144 hasConceptScore W2131966144C535046627 @default.
• W2131966144 hasConceptScore W2131966144C71924100 @default.
• W2131966144 hasFunder F4320319985 @default.
• W2131966144 hasIssue "3" @default.
• W2131966144 hasLocation W21319661441 @default.
• W2131966144 hasLocation W21319661442 @default.
• W2131966144 hasOpenAccess W2131966144 @default.

• next